• 1
    Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:115164.
  • 2
    Hsieh CS, Liang Y, Tyznik AJ, Self SG, Liggitt D, Rudensky AY. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity 2004; 21:26777.
  • 3
    Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 2003; 4:3306.
  • 4
    Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22:32941.
  • 5
    Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:105761.
  • 6
    Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol 2003; 4:33742.
  • 7
    Sakaguchi S. Animal models of autoimmunity and their relevance to human diseases. Curr Opin Immunol 2000; 12:68490.
  • 8
    Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:9719.
  • 9
    Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:27785.
  • 10
    Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4 (+) CD25 (+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54:929.
  • 11
    Seddon B, Mason D. Peripheral autoantigen induces regulatory T cells that prevent autoimmunity. J Exp Med 1999; 189:87782.
  • 12
    Garza KM, Agersborg SS, Baker E, Tung KS. Persistence of physiological self antigen is required for the regulation of self tolerance. J Immunol 2000; 164:39829.
  • 13
    Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:43140.
  • 14
    Tang Q, Henriksen KJ, Boden EK et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+ CD25+ regulatory T cells. J Immunol 2003; 171:334852.
  • 15
    Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3 (+) CD25 (+) CD4 (+) regulatory T cells by interleukin (IL) -2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201:72335.
  • 16
    Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:66574.
  • 17
    Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005; 6:15262.
  • 18
    Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004; 199:146777.
  • 19
    Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4 (+) CD25 (+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99:34939.
  • 20
    Tang Q, Henriksen KJ, Bi M et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199:145565.
  • 21
    Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonal human CD4 (+) CD25high regulatory T cells. Blood 2004; 104:895903.
  • 22
    Lin CH, Hunig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 2003; 33:62638.
  • 23
    Beyersdorf N, Gaupp S, Balbach K et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005; 202:44555.
  • 24
    Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25 (+) regulatory T cells convey suppressor activity to conventional CD4 (+) T helper cells. J Exp Med 2002; 196:25560.
  • 25
    Allan SE, Passerini L, Bacchetta R et al. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 2005; 115:327684.
  • 26
    O'Garra A, Vieira PL, Vieira P, Goldfeld AE. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest 2004; 114:13728.
  • 27
    Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182:20714.
  • 28
    Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Sakaguchi S. Immunologic self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10:196980.
  • 29
    Thornton AM, Shevach EM. Suppressor effector function of CD4+ CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164:18390.
  • 30
    Thornton AM, Shevach EM. CD4+ CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188:28796.
  • 31
    Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge. IL-2 is critically required for the in vitro activation of CD4+ CD25+ T cell suppressor function. J Immunol 2004; 172:651923.
  • 32
    De La Rosa M. Rutz S., Dorninger H. & Scheffold A. Interleukin-2 is essential for CD4+ CD25+ regulatory T cell function. Eur J Immunol 2004; 34:24808.
  • 33
    Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4 (+) regulatory T cell function. J Exp Med 2002; 196:8517.
  • 34
    Barthlott T, Moncrieffe H, Veldhoen M, Atkins CJ, Christensen J, O'Garra A, Stockinger B. CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. Int Immunol 2005; 17:27988.
  • 35
    Waldmann H, Cobbold S. Exploiting tolerance processes in transplantation. Science 2004; 305:20912.
  • 36
    Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4 (+) CD25 (+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med 2002; 196:24753.
  • 37
    Stassen M, Jonuleit H, Muller C, Klein M, Richter C, Bopp T, Schmitt S, Schmitt E. Differential regulatory capacity of CD25+ T regulatory cells and preactivated CD25+ T regulatory cells on development, functional activation, and proliferation of Th2 cells. J Immunol 2004; 173:26774.
  • 38
    Kerstan A, Hunig T. Cutting edge. distinct TCR- and CD28-derived signals regulate CD95L, Bcl-xL, and the survival of primary T cells. J Immunol 2004; 172:13415.
  • 39
    Scheffold A, Huhn J, Hofer T. Regulation of CD4+ CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol 2005; 35:133641.
  • 40
    Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, Collins M, Shevach EM. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+ CD25+ T cells. J Immunol 2004; 173:500820.
  • 41
    Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP. Triggering of OX40 (CD134) on CD4 (+) CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005; 105:284551.
  • 42
    Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3:93951.